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INTRODUCTION 
 
The  list  of  genetic  factors  pertinent  to  life‐span 
determination has been growing by leaps and bounds, to 
define age‐related physiological changes [1]. A steady 
loss of function in multiple vital organs has been shown 
to  correlate  with  aging,  accompanied  by  increased 
incidence  of  a  wide  range  of  diseases  such  as 
neurological  disorders,  metabolic  disorders  e.g. 
diabetes,  and  cancer  [2].  Modification  of  signaling 
cascades, such as highly conserved signaling pathways 
including  insulin/Insulin‐like  growth  factor  1  (IGF1), 
target  of  rapamycin  (TOR)  and  sirtuin,  for  enhanced 
cellular responses to stress, is recognized as key to life 
span extension and accompanying reduced age‐related 
pathology [3]. The search for biomarkers for aging has 
led  to  the  identification  of  unique  leads  in  blood 
samples,  a  relatively  noninvasive  method  to  acquire 
experimental specimens. However, the main findings in 
circulating  blood  reflecting  systemic  phenomena  are 
protein‐based changes, mostly connected to agerelated 
perils  such  as  cancer,  atherosclerosis,  and 
cardiovascular dysfunction [4]. A few studies linking 
blood‐based changes to normal aging involve a serum 
protein  pattern  that  proves  to  be  a  reliable  index  for 
aging  in  rat,  independent  of  pathologies  [5];  the 
techniques commonly used, 2‐D gel electrophoresis or 
proteomic  profiling,  have  led  to  identifying  various 
proteins as potent blood‐based biomarkers [6]. Another 
such example is the observation that circulating IGF‐1 
in centenarians with robust cognition is low [7], while 
those  suffering  Alzheimer‟s  disease  (AD)  show  high 
levels of this protein in their blood [8]. 
 
Non-coding  RNAs  are  prominent  epigenetic  factors, 
along  with  nucleic  acid  modifications  such  as  DNA  
methylation  and  histone/chromatin  modification  [9].  
Among  all  the  small  non-coding  RNAs, microRNAs 
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 (miRNAs)  have  been  studied  in  detail;  they  are 
generally transcribed by RNA polymerase II, rarely by 
RNA  polymerase  III  [10].  MiRNAs  modulate  protein 
regulation at the post-transcriptional level, because their 
seed sequences have perfect or partial complementarity 
to  the  coding  region  or  the  3‟-  untranslated  region 
(UTR)  of    one  or  more  target  mRNAs,  leading  to 
mRNA degradation in the former case, and inhibition of 
protein translation in the latter; either way, they serve as 
negative regulators of gene expression [10, 11]. Early 
studies illustrating the role of miRNAs in aging found 
that expression of C. elegans lineage  4 (lin-4) miRNA 
is  needed  for  extended  lifespan,  while  abridged 
expression leads to shortened lifespan [11,  12]. We also 
reported  a  set  of  miRNA  expressions  unique  to 
peripheral  blood  mononuclear  cells  (PBMCs)  of  AD 
victims [13], as well as changes in miRNA expression 
during  aging  in  brain  and  liver  of  mice  and  rats, 
including long-lived calorie-restricted and mutant mice 
with extended life span [14-17]. 
 
In  general,  blood  samples  can  be  separated  into  two 
major components: PBMCs, composed of lymphocytes, 
monocytes, megakaryocytes, platelets, etc.; and plasma 
or  serum,  depending  on  blood-  collecting  procedures 
(adding an anticoagulant produces the former instead of 
the latter). Our group has shown that miRNA profiles in 
PBMCs  of  AD  victims  differ  from  those  of  normal 
elderly controls (NEC); this led us to suggest that lead 
microRNAs  in  PBMCs  of  AD  victims  may  be 
biomarkers as a blood-based diagnostic for this disease 
[18].  In  cell-free  serum/plasma,  microRNAs  are 
repeatedly reported to be not only present [19], but also 
a  means  for    cell-cell  communication,  secretion,  and 
many other cellular functions associated with cell death, 
etc. [5, 20, 21]. Recently, major differences in miRNA 
expression between plasma microvesicles and PBMCs 
were  reported,  owing  to  the  origin  of  these  cell-free 
miRNA  expressions  in  the  former  case  [20].  Plasma 
miRNA expression is a predictive and diagnostic tool 
for  lung  cancer;    changes    in    plasma    miRNA  
expression  imply  staging  and  prognosis  [22].  Blood  
associated microvesicles contain miRNAs suggested for 
inter-cellular  and  inter-organ  communication  [23].  In 
brain, circulating microRNAs have been suggested to be 
vital  for  neuronal    communication  [24],  and  lead 
microRNAs in blood serve as circulating biomarkers for 
bipolar disorder and early Huntington‟s disease [25]. 
 
In this study we report that miR-34a levels in mouse 
PBMCs and plasma increase with age, as do those in 
brain,  starting  at  4  months  of  age,  as  documented  in 
samples from 2 days old till 25 months of age. Parallel 
study  of  miR-196a  shows  that  the  level  of  this 
microRNA  remains  stable  with  age  in  all  three 
specimens examined, and therefore serves as a control 
for  age-independent  regulation  of  its  expression. 
Corresponding  to  this  increase  of  miR-34a,  plasma  
expression    of    SIRT1,    the    major    target    of    this 
microRNA,  shows  a  precipitous  reciprocal  decrease 
starting  at  4  months  of  age,  while  PBMCs  exhibit  a 
gradual decrease in SIRT1 from this age onward.  In 
contrast, the SIRT1 level in brain rises from 20 days old 
till 4 months, and remains at this level without decrease  
until  12  months  of  age.  The  reciprocal  expression 
between miR-34a and SIRT1 in plasma samples is not 
observed with another target of this microRNA,  Bcl2,  
whose  expression  in  plasma  actually  declines  as  
early  as  7  days  after   birth  and continues to 25 
months, while in brain and PBMCs it shows a slight 
decrease    during    the  same  time  frame.  In  brief,  our 
results show here that levels of miR-34a in plasma and 
PBMCs  may  serve  as  a  non-  invasive  biomarker,  a 
circulating ‟footprint‟ of brain aging; in particular the 
rise in the plasma is detected as early as 4 months of 
age, before any impending decline in this organ begins. 
 
RESULTS 
 
Expression  levels  of  miRNAs  in  blood  and  brain 
samples of C57/B6 mice 
 
Mouse  microRNA  34a  (mmu-miR-34a)  expression 
increases in brain of older rodents, while a decline in its 
expression  over  age  is  linked  to  longevity  in  calorie-
restricted mouse brain [13, 16] . SIRT1 and Bcl2 are 
two major target genes suppressed by miR-34a [17, 26]. 
In contrast, although miR-196a is elevated  in  Crohn‟s 
disease  [27],  changes in its  level of  expression during 
mouse aging is  not yet reported.  Thus,  our study of  
microRNA  expression over a  life span from neonatal 
to  old age was performed with miR-34a as our focus of 
interest, and miR-196a as a control. 
 
Total RNA samples extracted from PBMCs, plasma and 
brain specimens from age groups from 2 days to  25 
months were reverse transcribed for quantitative PCR 
(qPCR) to determine their levels of mmu-miR-34a and 
mmu-miR-196a.  qPCR  for  these  two  miRNAs  was 
performed  using  total  RNA  samples  from    all  three 
specimens    (Supplemental  Figure  1-2);  composite 
graphs of  expression of  these two miRNAs are shown 
in Figure 1. Levels of miR-34a are stable from 2 days 
till 4 months, with subsequent rises in all three tissues; 
the  increases  in  brain    and  PBMCs  exhibit  a  similar
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gradual  trend,  while  the  increase  in  plasma  samples 
rises steeply starting at 4 months. All assays for each 
animal  were  repeated  three  times,  and  three  animals 
were  used  per  age  group;  thus,  the  qPCR  results 
presented here were calculated from nine data points, 
with three repeats of three different  animals. In contrast 
to the increased miR-34a expression with age, levels of 
miR-196a  remain  stable    throughout  all  age  groups 
studied  here,  from  2  days  till  25  months  of  age. 
Statistical analysis for each age group is presented in 
Supplemental Table 1. 
 
Inverse levels of expression between miR-34a and its 
target, SIRT1, in blood and brain during aging 
 
MicroRNA-34a regulates SIRT1 expression both at  the  
pre-transcriptional  level,  by  regulating expression of 
transcription  factor  SP1  [16],  and  also  at  the  post-
transcriptional level, by binding to the 3‟ untranslated  
region (UTR)  of  SIRT1 transcript [28] to  repress its  
expression.  Total  protein  samples  extracted    from 
plasma, PBMCs, and brain were subjected to Western 
blot  analysis  to  determine  a  possible    inverse  
relationship    between    SIRT1    and    miR-34a    levels  
from  2  days  to  25  months  old. Decreased SIRT1 
expression  was  observed  in  both  plasma  and  PBMC 
samples at 4 months of age, with the former showing a 
precipitous drop in SIRT1 abundance (Figure 2A & B). 
However,  levels  of  SIRT1  in  brain  increase  from  a 
steady state during the postnatal period to a stable high 
level from 28 days to 12 months, before decreasing to 
25 months (Figure 2C). A  composite graph depicting 
the expression trends in the three specimens across all 
age groups shows the  precipitous decline in plasma, but 
gradual decline in PBMCs from 4 months on, and the 
brain-specific rise at 28 days followed by the decline at 
12 months old (Figure 2D). In all, the only sharp inverse 
relationship  detected  at  early  adult  life  (4-months)  
between miR-34a and its target,  SIRT1,  is  observed  
in  plasma.  All  immunoblots  were  further  verified  
by   densitometric measurements of three repeats with 
three  different  animals  of  the  same  age  group,  after 
normalization with ß-actin in brain and PBMC samples. 
Ponceau  S  stained  bands  were  used  to  validate  equal 
loading, and selected bands showing consistent levels 
across  the  blots  were  used  to  normalize  SIRT1 
expression  in  plasma  samples.  The  individual  graphs 
may  be  found  as  supplemental  data  (Supplemental 
Figure 3). 
 
Expression of miRNA-34a and its target SIRT1 in 
brain  tissue  sections  from  middle  and  old  age 
C57/B6 mice 
 
A  lack  of  age-dependent  increase  in  miR-34a 
expression  in  the  hippocampal  region  has  been 
previously  reported  in  calorie-restricted  mice,  as 
compared  to  littermate  wild  type  (WT)  controls  [17]. 
Here, we performed similar in situ histochemical (ISH) 
determination of miR-34a, to validate the qPCR results 
with  total  brain  RNA  studies  by  locked  nucleic  acid 
(LNA)  probes  for  this  microRNA.  Two  selected  age  
groups,  10  and  31  months,  were  chosen  to  represent 
specimens  before  SIRT1  decreases,  and  beyond  the 
maximal decline. Brain sections of these two age groups 
were processed for levels of miR-34a expression by in 
situ hybridization, binding with a locked nucleic acid 
probe  for  miR-34a,  as  well  as  a  control    probe  for 
background binding reaction (Figure 3 A & B). 
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Figure 1: Age‐dependent expression levels of two miRNAs in blood and tissue samples of 
C57/B6 mice  A  graphical  representation  of  expression  levels  of  miRNAs  using  qualitative  PCR, 
represented as 1/ΔCt values as box plots for brain, PBMC and plasma samples. Age groups included 
are from early to old age [from 2 days (d) to 25 months (m)]. Panel (A) shows composite graphs for 
expression of miR‐34a, while panel (B) shows the levels of expression of miR‐196a in brain, PBMCs, 
and plasma. (n = 3; three different animals were used from each age group selected for the study.)  
 
 
 
 
 
 
 
 
 
Intensity of LNA probe reaction was most noted in the 
hippocampus, more than the cortex, in both age groups. 
This  intensity  differential  was  further    verified  by  
densitometric  measurements    of    three  serial  sections 
each  from three  different animals  of  the  same  age  
groups  (Figure  3C).  Expression data  obtained  using  
in  situ  hybridization confirmed the qPCR results, and  
validated  the  trend  of  increased  miR-34a  expression 
from 10 to 31 months of age in brain. 
 
Immunostaining to detect SIRT1 in middle and old age, 
i.e. 10 and 31 months respectively, was performed on 
sister specimens of those used for in situ hybridization 
with  the  LNA  probe  for  miR-34a.  Decreased  SIRT1 
from 10 to 31 months was observed most significantly 
in hippocampus, validating the inverse relationship with 
miR34a expression in brain, described by the grind-and-
find  qPCR  assays  and  Western  blotting  for  SIRT1 
levels. Figure 3D-G shows in situ hybridization results 
of  heightened  miR-34a  expression  in  hippocampus,  
corresponding  to  decreased  SIRT1  presence.  All 
immunostaining  results  were  further  verified  by 
densitometric measurements of three repeats with three 
different animals (n = 3) (Figure 3 C, H). 
 
Levels of Bcl-2, another target of miR-34a, in blood 
and tissue samples of C57/B6 mice. 
 
Another target of interest of miR-34a is Bcl2. Western 
blots for 26 kilodalton Bcl2 expression were performed 
using  protein  samples  of  brain,  PBMCs  and  plasma 
from all age groups used for the qPCR assays of the two 
microRNAs. A decline in Bcl2 was observed starting as 
early as 7 days after birth in plasma (Figure 4 A-C), 
continuing until old age at 25 months. In contrast, Bcl2 
in  brain  and  PBMCs  show  stable  abundance,  with  a 
gradual decrease from 2 months to old age. A composite 
graph  showing  the  decline    in    Bcl2    is    shown    in  
Figure  4D;  the  individual  graphs  may  be  found  as  
supplemental  data  (Supplemental  Figure  4).  
Interestingly, the decrease of Bcl2 in plasma starts at 7 
neonatal  days,  and  continues  its  downward  trend  in 
plasma samples. All immunoblot data were verified by 
densitometric measurements of three repeats with three 
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Figure 2: Age‐dependent expression levels of SIRT1 in blood and tissue samples of C57/B6 mice Western blot 
analysis of SIRT1 expression in age groups from 2 days (d) to 25 months (m); panels (A) SIRT1 expression in plasma samples 
normalized  with  selected  Ponceau  S  stained  band,  showing  constant  levels  for  all  samples  used,  along  with  histograms 
presenting  average  densitometric  values,  (B)  SIRT1  expression  in  PBMC  samples  normalized  with  β‐actin,  along  with 
histograms presenting average densitometric values, (C) SIRT1 expression in brain samples normalized with β‐actin, along with 
histograms presenting average densitometric values, (D) Composite graph presenting SIRT1 expression in plasma, PBMC and 
brain samples. (*p < 0.01, **p < 0.0001; all histograms represent Mean ± SD; n = 3; three different mice used from each 
selected age group.)  
 
 
 
 
 
 
 
 
 
different  animals,  after  normalization  with  ß-actin  for 
tissues and PBMC samples. For normalization of Bcl2 
expression in plasma samples, Ponceau S stained bands 
were used to confirm equal loading (n = 3). 
 
Age-dependent  changes  of  levels  of  p53  and  its 
acetylated  form  in  blood  and  brain  samples  of 
C57/B6 mice. 
 
SIRT1  is  an  evolutionarily  conserved  molecule  with 
deacetylation properties; one of its targets is p53, whose 
acetylation leads to increased transcriptional activation 
of miR-34a expression [29]. Western blot analysis was 
performed  using  total  protein  samples  from  PBMCs, 
plasma and brain from mice aged 2 days to 25 months. 
Expression of p53 and its acetylated form was detected; 
Ponceau S stained bands for plasma samples and ß-actin 
for  PBMCs  and  brain  were  used  as  normalization 
controls  (n  =  3).  Figure  5  shows  levels  of  total  and 
acetyl-p53  in  plasma  (panel  5A),  PBMCs  (panel  5B) 
and brain (panel 5C), with the percentage of the latter in 
the total protein pool illustrated in Panel 5D. The acetyl-
p53  proportion  remains  stable  from  2  days  until  2 
months in both plasma and PBMC specimens; this is 
followed  by  a  steady  increase    between  4  and  12 
months, after which it stays the same in the remaining 
old  age  groups,  as  observed  in  brain.  The  acetyl-p53 
fraction in brain exhibits a steady increase from 2 days 
old till old age. Interestingly, proportions of acetyl-p53 
in  the  total  p53  protein  pool  in  all  three  specimens, 
plasma, PBMCs, and brain, are  similar from 12 to 25 
months of age, again suggesting that circulating blood 
Figure 3: Expression of miRNA‐34a and SIRT1 in brain tissue sections from middle and old age C57/B6 mice In situ 
hybridization  detected  miR‐34a  expression  using  LNA  probes.  Panels  (A)  and  (B)  show  expression  of  miR‐34a  in  cortex  and 
hippocampus of 10 and 31 month old mice. Scrambled LNA probes were used as control for this experiment (Image not shown); (C) 
graphical presentation of mean intensity values of miR‐34a expression in cortex and hippocampus of 10 and 31 month old mice, by 
immunostaining assay to detect SIRT1 expression. Panels (D‐E) and (F‐G) show expression of SIRT1 in cortex and hippocampus of 10 
and 31 month old mice, by DAPI staining to detect nucleus and section integrity (Image not shown); (H) graphical presentation of 
mean intensity values of SIRT1 expression in cortex and hippocampus of 10 and 31 month old mice. (*p < 0.01, **p < 0.0001; all 
histograms represent Mean ± SD; n = 3; three different biological samples from each age group.) 
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acetyl/total p53 may be an additional systemic marker 
for age-related changes in brain. 
 
DISCUSSION 
 
Central to our findings is the observation that miRNA-
34a expression in PBMCs and brain shows concordant 
steady increase from neonatal to old age, with levels of 
miR-34a in plasma showing a sharp rise from  4  to 25 
months of age. This rapid gain of miR-34a in plasma is 
inversely  related  to  SIRT1  abundance  in  this  blood 
specimen,  which  declines  precipitously  from  4  to  25 
months. However, in brain and PBMCs, this reciprocal 
expression  between  increased  miR-34a  and  decreased 
SIRT1 is not observed until after 12 months of age. This 
pattern, starting at 4 months in plasma and 12 months in 
brain and PBMCs, is not observed with another major 
target of this microRNA, Bcl2, whose downward trend 
starts  at  neonatal  time  in  plasma,  while  in  brain  and 
PBMCs it remains stable. In situ hybridization data and 
histochemical studies indicate the hippocampus as the 
venue  of  the  most  prominent  local  increase  in 
expression  level  of  miR-34a  with  age,  and  reciprocal 
decrease of SIRT1 in the same brain region in old mice 
[26].  Taken  together,  our  results  suggest  that:  1. 
Increased levels of  expression of miR-34a in plasma 
and PBMCs correspond to those observed in brain, with 
the former most dramatically preceding the latter two; 
and 2. the sharp increase in plasma miR-34a, and the 
decrease of SIRT1,  starting at 4 months of age, may 
serve  as  noninvasive  biomarkers  for  impending  age-
dependent brain decline at 12 months or later in mice. 
 
The major difference between the two blood samples, 
PBMCs and plasma, is the source of their RNA  and  
protein  specimens.  PBMCs  largely  consist  of  cells  
making  up  this  component,  including lymphocytes,  
monocytes,    macrophages,    etc.,    while    plasma  
components  are  released  from  various tissues into 
circulating  blood through secretion, exocytosis, cell-to-
   
www.impactaging.com                990                                        AGING, October 2011, Vol.3 No.10 
Figure 4: Age‐dependent expression levels of Bcl‐2 in blood and brain tissue samples of C57/B6 mice Western blot 
analysis for Bcl‐2 levels in age groups from 2 days (d) to 25 months (m); panels (A‐B‐C) Bcl‐2 expression normalized with Ponceau S 
stained bands in plasma, and with β‐actin in brain and PBMC samples, along with histograms presenting average Bcl‐2 expression 
densitometric  values;  (D)  Composite  graph  presenting  Bcl‐2  expression  in  plasma,  PBMC  and  brain  samples  as  average 
densitometric intensity. All graphs represent Mean ± SD. n = 3; three different mice from each age group.  
 
 
 
 
 
 
 
 
cell communication, and even cell death, including both 
apoptosis and necrosis [30].  Thus, in mammals, cell-
free plasma RNA and protein may be true „foot-prints‟ 
of  the  entire  organism‟s  health  status.  Obviously, 
changes in PBMC RNA and protein  profiles  follow  
the  same  age-dependent  regulation  as  other  organs,  
i.e.  cell-type  specific. Nevertheless, our observations 
suggest that increased levels of miR-34a in PBMCs and 
plasma  may  be  a  noninvasive  biomarker  reflecting 
changes in brain during aging, with increased levels of 
this microRNA in plasma potentially serving as an early 
biomarker for impending changes in the brain. 
 
Functionally,  miR-34a  is  well  recognized  as  a  tumor 
suppressor in brain and many other tissues; its absence 
is associated with neoplastic growth, including glioma 
and  brain  tumor  [31],  explaining  the  needed  increase 
during early adult life for protection against neoplasms 
of  many  cell  types,  including  those  in  the  central 
nervous  systems  (CNS).  However,  its  continuing 
increase  presents  a  classical  case  of  antagonistic 
pleiotropy, i.e. a  genetic trait beneficial in early life but 
posing adverse consequences in later life. This is largely 
due to the fact that, as do many other miRs, miR-34a 
silences multiple targets, suppressing cell-cycle traverse 
genes such as cdks and cyclins; but its silencing action 
on  SIRT1  may  be  the  most  detrimental  [31-33].  
Although the notion of a direct role for SIRT1 and its 
sisters in extending life  span  has  come  into  question  
recently  [34],  they  clearly  suppress  age-dependent  
pathologies,  reducing  diabetes,  obesity, 
neurodegeneration,  etc.  [35].  Thus,  miR-34a‟s 
continuing  rise  in  late  life  may  cause  a  reduction  of 
SIRT1, a loss ill afforded by older organisms [35-37]. 
 
Complicating further the see-saw relationship between 
miR-34a  and  SIRT1  expression  is  the  role  of  p53  as 
transcriptional activator for this microRNA‟s expression 
[33]. Activation of miR-34a is regulated via binding of  
acetylated  p53,  which  in  turn  is  controlled  by 
deacetylation  by  mammalian  SIRT1,  thus  forming  a 
feedback  loop  [33].  At  first  glance,  our  results  may 
suggest that this loop may be disrupted in older mouse 
brain and PBMCs, as well as in many other tissues with 
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Figure 5: Age‐dependent changes in ratio of acetylated to total p53 in blood and brain samples of C57/B6 mice. 
Western blot analysis of acetylated p53 proportion in age groups from 2 days to 25 months; Panels A, B, and C show acetylated 
P53  proportion  normalized  with  Ponceau  S  in  plasma  (Panel  A),  and  with  β‐actin  in  PBMCs  and  brain  samples,  along  with 
histograms presenting the average densitometric values. Panel D presents a composite graph of the percentage of acetylated P53 
expression in the total p53 protein pool in plasma, PBMC and brain samples. (*p < 0.01, **p < 0.0001; all histograms represent 
Mean ± SD; n = 3; three different biological samples from each age group)  
their „foot-print‟ in the plasma, due to increased miR-
34a,  decreased  Sirt1  levels,  and  increased  levels  of 
acetylated p53. However, a recent report  by  Lee,  et  
al.  [36]  of  activation of  nuclear  bile  acid  receptor,  
Farnesoid  X    Receptor    (FXR),  recruiting  the  Small 
Heterodimer Partner (SHP) to the p53  binding site in 
miR-34a‟s promoter region, and  thus  preventing  this  
microRNA‟s    activation    and    its    downstream  
suppressing  action  on  SIRT1, presents  yet  another  
layer    of    control.    Abnormality  of    this    positive  
feedback  between  FXR/SHP  to decrease miR-34a and 
increase  SIRT1  is  observed  in  many  age-related 
metabolic  diseases  [36].  Our  finding    of    continuing  
rise    of    miR-34a    with    age    suggests  that    either  
continuing  acetyl-p53    increase  overwhelming  the  
SHP-binding  or  other  putative  factors  involved,  thus 
disable the FXR/SHP role in inhibiting this microRNA  
activation,  and  cause  the  absence  of  SIRT1  in  many 
age-related metabolic diseases. 
 
As noted above, among the various functional impacts 
of  p53,  from  tumor  suppression  to  induction    of 
apoptosis,  there  emerges  yet  another  vital  role  in 
regulating signaling networks through controlling miR-
34a transcription activation. This adds to the complexity 
of how p53 governs life span determination; contrasting 
scenarios report high tumor incidence in p53 knockout 
mice,  thus  shortening  life  span,  while  p53 
overexpression    induces  accelerated  aging  [38,  39]. 
Therefore, p53 regulation is another case of antagonistic 
pleiotropy,  protective  in  the  young  but  deleterious  in 
older  organisms.  For  example,  in  the  context  of 
regulating  intertwining  networks,  p53  seems  to 
participate in life extension as a  downstream  activator  
for    apoptosis    in    the    well-known    IGF1/mTOR  
pathway,    suppressing    tumor  development;  but  its 
continuous  increase  in  older  life  may    overwhelm  
SHP‟s binding  to  miR-34a  and  become  the  dominant 
activator  for  miR-34a,  resulting  in  the  SIRT1    loss 
described above. To further thicken the soup, in a large 
human  population  study  of  p53  polymorphism,    the  
p53-P72  genotype  is  associated  with  reduced  fertility 
and increased longevity [40]. In brain, the role of p53 is 
associated  with  cognitive    robustness,  by    regulating 
glucose  metabolism,  as    well  as    neuronal  apoptosis,  
eliminating deleterious,  damaged  neurons  to  make  
room    for    neurogenesis    [40].    Here,    SIRT1    is  
involved  in neuroprotective  signaling,  reducing  the  
formation  of  ß-amyloid,  the  pathogenic  form  of  
amyloid precursor   protein  (APP),  one  of  the  two  
main  diagnostic  histopathologies  of  AD,  along  with 
neurofibrillary    tangles.    Paradoxically,  ß-amyloid 
activates  p53,  which  in    turn  activates  miR-34a  and 
suppresses    SIRT1  [41],    as    one  of  the    putative 
mechanisms  underlying  accelerated  aging  when  this 
tumor-suppressing  transcriptional    factor  is 
overexpressed. The complexities presented here in p53-
dependent regulation, and how miR-34a participates in 
this puzzle for brain aging, will demand future system 
biology  investigation  to  unravel  their  mysterious  but 
fascinating  roles  in  regulating  aging  and  life  span 
determination.  Nevertheless,  our  finding  of  the 
continuous increase of both acetyl-p53 and miR-34a in 
blood  and  brain  during  aging  suggests  them  as  two 
noninvasive biomarkers for aging in the central nervous 
system. 
 
Circulating microRNAs, specifically  in  plasma,  may  
reflect    particular    disease    states    such    as  cancer,  
cardiovascular    disorders,  and    even    neuronal  
dysfunction    [18,    29].    Increases    of    miR-34a    in 
various tissues during aging are well recognized in our 
own work and that of others, from liver to brain, and 
even in autopsy  brains and PBMCs of AD victims [13, 
16].  Our  previous  report  [13]  documented  increased  
expression  of    miR-34a    in    AD    patients‟  PBMCs, 
compared to  NEC,  associated with  allelic inheritance 
of APOE4 [19, 42].  Although this systemic change in 
miRNA  expression  in  PBMCs  of  AD  patients  is  of 
prime significance, expression profiles in PBMCs may 
also  indicate  changes  in  the  immune  system  in 
Alzheimer‟s disease [42]. This notion led to the recent 
suggestion  that  aberrant  inflammation  is  an  vital 
underlying  AD  pathogenesis,  challenging  the  popular  
emphasis  on  amyloid  plaques  as  the  essential  
manifestation  of  the disease [43]. The  kernel of  this  
suggestion    is    the  overexpression  of  cytokine 
interleukin-1 (IL-1) by microglia in the brain, thought to 
lead to  neuronal deterioration in Alzheimer‟s disease 
[44]. Interestingly, upstream regulators for IL-1, i.e. IL-
6  and  IL-8,    are  secreted  by  senescent  fibroblasts, 
associated  with  miR-146a/b,  key  microRNAs 
controlling  inflammatory    response  [45].  Moreover, 
increased  miR-146a  is  noted  in  AD  brains  and  the 
brains  of  older  mice,  perhaps  due  to  increased 
inflammatory response [46]. Linking the secretion from 
senescent  fibroblasts  to  brain  aging  and  
neurodegeneration    may    suggest    that    heightened  
inflammatory    response    in    aged    animals    and 
Alzheimer brain is a systemic manifestation involving 
all tissue types; plasma samples may be the best source 
to identify the factors involved. Future work using our 
same approach, i.e. baseline studies of the composition 
of  this  blood    component,  with  miR-146a  and  others 
secreted  by  cells  such  as  senescent  fibroblasts,  may  
yield  more  blood-based,  age-dependent  biomarkers  
in  the  category  of  increased inflammatory response. 
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Clearly,  the  present  study  is  not  comprehensive, 
covering  all  the  miRNAs  found  in  either  PMBCs  or 
plasma as biomarkers of brain aging, as noted above for 
miR-146a.  However, our finding of miR-34a increasing 
monotonically  with  age,  as  a  first  example, 
demonstrates that circulating blood is a powerful and 
accessible window to visualize changes in vital organs 
which are not otherwise available, in the case of human 
studies  during    aging.  Including  our  own  work  with 
Alzheimer‟s  disease  (AD),  most  human  studies  are 
limited  by  available  resources  and  time  required,  and 
thus  designed  with  a  cross-sectional  approach, 
comparing disease victims with  age-matched controls, 
as reviewed by Provost, 2010 [47]. Longitudinal follow-
up studies are rare and costly, and thus most microRNA 
studies for AD pathogenesis are limited to autopsy brain 
samples and animal models. Neither approach is ideal; 
the former is noted for its graveyard nature, imperfect 
neither  for  disease  initiation  nor    progression,  and 
animal  models  mostly  use  transgenic  mice  carrying 
human APP and/or Tau mutations mostly composed of 
familial AD polymorphisms as surrogates.  The present 
work  shows  baseline  concordant  changes  between 
PBMCs,  plasma    specimens,    and    brain,    thus  
validating  our  human  peripheral  blood  sample  study  
with  AD patients,  pointing  to  circulating RNAs as  an 
accessible and noninvasive  biological source to  detect 
changes  in  brain.  In  particular,  changes  in  plasma 
microRNA profile may occur much earlier, seen here at 
4  months,  than  the  impending  decline  in  brain.    Our 
study presents the first example that circulating blood 
microRNAs,  exemplified  by  miR-34a,  may  serve  as 
biomarkers for brain aging. The RNA samples collected 
for this study will be an invaluable resource, when the 
entire repertoire of microRNA profiles from birth to old 
age in  mice is obtained by future studies using deep 
sequencing;  data  obtained  will  serve  as  a  baseline 
database  for  animal  disease  model  studies  in  general, 
and as a possible surrogate for human studies as well, 
because  of  the  cross-species  conserved  nature  of  this 
noncoding RNA species. The present study paves the 
way  for  the    ultimate  discovery  of  tissue-specific 
biomarkers  in  blood  samples  for  inaccessible  organs 
such as brain, and possibly even blood-based universal 
biomarkers for entire organismic aging. 
 
MATERIALS AND METHODS 
 
Animals and Tissue Collection 
 
Mice  of  the  C57/black  6  strain,  from  2  days  till  31 
months  old,  were  used  in  this  study.  For 
immunohistochemistry and in situ hybridization assays, 
brains of males 10 and 31 months old were used, while 
the other assays used 2 days old till 25 months  (2, 7, 
14, 20 and 28 days, 2, 4, 12, 18, and 25 months).  All  
animal    work    was    approved    by    institutional  
(University  of  Louisville)  biosafety  board protocol  
#05-001.  Brain  and  blood  specimens,  including  both  
peripheral    blood    mononuclear    cells  (PBMC)  and 
plasma, were obtained from at least three mice of each 
age group. 
 
Processing blood for PBMC and plasma fractions 
 
After  collection,  individual  mouse  blood  specimens 
were  layered  onto  Ficoll-Paque  Plus  solution  (GE 
Healthcare,  Piscataway,  NJ),  containing  EDTA  to 
prevent coagulation, and centrifuged for 30 minutes at 
1,500  x  g    to    separate  the  blood  samples  into  four 
layers, the plasma in the upper layer the next PBMC-
containing fraction, as the white layer, then the Ficoll-
Paque  plus  solution  with  the  red  blood  cells  at  the 
bottom.  The  plasma    and  PBMC  fractions  were  then 
collected and stored at -80
oC until further processing for 
RNA and protein isolation. 
Snap-frozen coronal brain sections were homogenized 
with  Trizol  reagent  (Invitrogen,  Carlsbad,  CA), 
followed by the total RNA isolation, in parallel with the 
isolated PBMC specimens, with the RNease Mini Kit 
(Qiagen,  Valencia,  CA).  The  isolated  RNA  fractions 
were then dissolved in RNase-free water and stored at -
80
oC    until  use.  The  quality  of  the  isolates  was 
determined by the Agilent 2100 Bioanalyzer with the 
Agilent  RNA  6,000  Nano  kit  (Agilent  Technologies, 
Foster City, CA) by the RNA integrity number (RIN); 
samples with values > 7 are of acceptable integrity. 
 
The RNA fraction was isolated by adding 0.75 ml of 
Trizol LS reagent (Invitrogen, Carlsbad, CA) to 0.25 ml 
plasma, followed by incubation at room temperature for 
5  min.  To  this  solution,  0.2  ml  of  chloroform      was  
added;    after    vigorous    mixing,    it    was    further  
incubated  for  5  minutes  at  room temperature, before 
centrifugation at 15,000 x g for 15 min at 4
oC, to obtain 
the RNA aqueous phase. This  was  collected,  and  after  
addition  of  0.5  ml  isopropanol  (Sigma,    St.    Louis,  
MO),  RNA  was precipitated and collected by further 
centrifugation    to  a  pellet,  before  washing  with  75% 
alcohol and storage in  RNase-free water. Since plasma 
contains little or no 28S or 18S RNA, the integrity of 
the  isolated  RNA  was  determined  by  the  small  RNA 
peak between 0 and 150 nt (Supplemental Figure 5C). 
Concentrations  of  RNA   specimens  isolated  from  
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brain,    PBMC    and    plasma    were    determined    by 
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 
 
Determination of microRNA expression levels 
 
Primers  specific  for  miR-34a  and  miR-196a  were 
obtained from Applied Biosystems (Foster City, CA) to 
perform quantitative RT-PCR (qPCR), according to this 
vendor‟s  protocol  for  TaqMan  microRNA  assays. 
Isolated  total  RNA  fractions  from  brain,  PBMC  and 
plasma were initially processed for reverse transcription  
(RT)  using   two  miRNA-specific  primers  (miR-34a:  
AB  Assay  IDs  000426;  miR-196a: 241070_mat) to 
obtain their RT products, used subsequently for qPCR 
analysis on a 7500 Fast System Real-Time  PCR  cycler  
(Applied  Biosystems).  Small  RNA  202  was  used  as  
control    to    calculate    the  expression    levels  of  two 
microRNAs, miR-34a and -196a in isolated biological 
specimens.  Numerical  indices  of    these  expression 
levels  are    expressed  by    the    1/ΔCT    method,  and  
obtain  the    values  for  individual  microRNA    after 
subtraction of the CT value for snoRNA202 (AB assay 
ID 001232, Applied Biosystems). 
 
Isolation of Protein fraction from brain, PBMCs and 
plasma 
 
Sister blocks of brain coronal sections used for RNA 
isolation  were  used  for  protein  extraction.  In  brief,  
brain specimens of ~100 µg were solubilized in 300 µl 
RIPA  buffer  before  isolating  the  protein  fraction,  as 
described  in  our  earlier  report  [16].    For  the  PBMC 
specimens,  the  organic  phase  after  RNA  isolation,  as 
described above, was dialyzed on Spectra Pro 6 dialysis 
membranes  (Spectrum  Laboratories  Inc.,  Rancho 
Dominguez, CA) in 0.3% SDS buffer at 4°C until the 
precipitate  was  completely  dissolved,  with  further 
incubation in 0.1% SDS solution for an additional 24 
hours.  Plasma  contains  a  huge  amount  of  serum 
albumin  and  immunoglobulin  (IgG);  these  were 
removed  by  the  Vivapure  anti-human  albumin  serum 
(HAS)/IgG  kit  (Sartorius    Stedim  Biotech  GMbH, 
Göttingen, Germany). BCA protein assays from Pierce  
Biotechnology  Inc    (Rockford,    IL)    were  used  to 
determine  the  concentrations  of  the  isolated  protein 
samples from brain, PBMC and plasma. 
 
Immunoblotting  for  protein  levels  of  SIRT1,  Bcl2 
and p53 
 
SIRT1 and Bcl2, two main targets of miR-34a, and the 
activator of this microRNA, acetyl-p53, as well as the 
total p53 protein pool were selected for determination of 
their protein abundance in brain, PBMC and  plasma. 
Twenty-five  micrograms  of  isolated  protein  samples 
from these three specimens were used for SDS-PAGE; 
afterwards, the electrophoretically separated bands were 
transferred from the gels  to  nitrocellulose  membranes  
(Schleicher  &    Schuell  BioScience,  Keene,  NH). 
Identification and quantification of the three proteins of 
interest were performed by incubating the membranes 
with  antibodies    including  rabbit  anti-SIRT1  (1:500, 
75435, Abcam Inc., Cambridge, MA), rabbit anti-Bcl-2 
(1:100,  2870,  Cell    Signaling,  Danvers,  MA),  rabbit 
anti-acetyl-p53  (1:500,  06-758,  Upstate  (Millipore), 
Billerica, MA), rabbit anti-p53 (1:500, SC-6243, Santa 
Cruz  Inc.,  CA)  and  rabbit anti-ß-actin  (1:1000,  8226, 
Abcam Inc., Cambridge, MA) overnight at 4°C. ß-actin 
was  used  as  a  loading  control  for  PBMC  and  brain 
specimens, but not for plasma protein samples,  since 
this  protein‟s  levels  in  plasma  are  not  always  stable. 
Instead, we selected a stable band with equal intensities 
across all lanes by Ponceau S staining [48].  Blots  were  
developed  following the  method  published  previously 
[17],  and  levels  of  protein abundance   were  detected  
by  the  Enhanced  Chemiluminescence  (ECL)  method,  
according  to  the manufacturer‟s  instructions (Pierce 
Biotechnology, Rockford, IL). The intensities of bands 
on  the  ECL-  developed  films  were  quantified  by 
densitometry  using  ImageQuant  software  (Molecular 
Dynamics Inc. Sunnyvale, CA). 
 
Localization  of  miR-34a  distribution  by  in  situ 
hybridization in brain 
 
A microRNA 34a-specific locked nucleic acid (LNA) 
conjugated  with  digoxigenin  (DIG),  and  a  scrambled   
control,    were    purchased    from    Exiqon    (Woburn,  
MA;  miR-34a  LNA  probe:  38487-05; Scramble-miR 
LNA  probe: 99004-01).  These  probes  were  incubated 
with the snap-frozen coronal brain sections, following 
our  reported  protocol  [3].  Bound  LNA  probes  were 
revealed by further incubating the sections with sheep 
anti-digoxigenin  (DIG)  antibody  conjugated  with 
alkaline  phosphatase  (AP)  (1:2000;  Roche,  
Indianapolis, IN) at 4°C overnight, followed by further 
detection  of  the  DIG-AP  substrate  by 
nitrobluetetrazoliumchloride  (NBT)/5-bromo-4-
chloro-3-indolyl phosphate,  toluidine  salt 
(BCIP). Positive signal of the distribution of the LNA 
probes  was  detected  by  microscopic  visualization, 
followed  by  image  quantification  with  densitometry 
software  (ImageQuant  version  5.2,  Molecular 
Dynamics). 
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Selected  segments  of  images  in  the  hippocampal  and 
cortical  regions  were  evaluated  for  miR-34a  labeling 
intensity,  compared  to  the  scrambled  control  probe. 
Image quantification was performed using three animals 
per age group; the intensities of the LNA probes were 
obtained  numerically  from  three  repeats  with  three 
serial sections each.  Thus, the final intensities for the 
two probes in each age group were obtained  from three 
different animals, to control for inter-animal difference, 
and three repeats with three serial sections to control for 
inter-experiment variation. The scrambled control was 
used to normalize for background labeling noise. 
 
Immunohistochemistry  localization  of  SIRT1 
distribution in brain 
 
Sister serial  sections  to  those  used  above  for  in  situ  
hybridization were  processed to  the determine  SIRT1 
distribution  by    initially  fixing  them  with  4%  
paraformaldehyde  (PFA),    followed  by  blocking  with 
10%  goat  serum  (Invitrogen,  Carlsbad,  CA)  and 
incubation  with  rabbit  anti-SIRT1  at  1:200  dilution 
(75435,    Abcam  Inc.,  Cambridge,  MA)  at  4°C 
overnight. The bound antibody was revealed by further 
incubation  with    goat  anti-rabbit  (1:400;  Invitrogen) 
conjugated  with  Alexa  fluor  594  for  40  minutes    at  
37°C.  Antibody  labeling  was  evaluated on  a  Zeiss  
fluorescence  microscope  (Carl    Zeiss,  Brighton,  MI) 
and AxioVision Rel.4.6 imaging system; image analysis 
of the distribution and intensities of SIRT1 protein in 
brain specimens of the two age groups follow the same 
procedure described above. 
 
Data Analysis for statistical significance 
 
The 1/ΔCT values of qPCR results for the expression 
levels  of  miR-34a,  miR-196,  and  controls  among  
different age groups were analyzed by Student‟s t tests, 
with  p  values  <  0.05  as  statistically  significant  
difference between any two groups presented in all the 
graphs for this assay. ANOVA was used to analyze data 
from all age groups included in all the assays. Mean ± 
standard  deviation  (SD)  was  calculated  for  data 
obtained  from  quantitative  evaluation  for 
immunoblotting,  in  situ  hybridization  and 
immunofluorescence  assays.  Data  analysis  for  these 
results proceeded as described for qPCR values.  In all 
experiments,  three  different  animals  were  used,  to 
control  for  inter-animal  variation;  some  of  them 
performed  three  repeats,  to  control  for  inter-assay 
variance. 
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S‐Figure 1: Age‐dependent levels of miRNA‐34a expression in various tissues in C57/B6 mice Panels 
(A‐B‐C) present box plot graphs of miR‐34a expression in plasma, PBMCs and brain samples, along with graphs 
of the 1/delta CT trend. (n = 3; three different animals were used from each age group selected for the study.) 
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S‐Figure  2:  Age‐dependent expression  levels  of  miRNA‐196a  in  various  tissues  of  C57/B6  mice  Panels 
(A‐B‐C) present box plot graphs of miR‐196a expression in PBMCs, plasma and brain samples, along with graphs of the 
1/delta CT trend. (n = 3; three different biological samples from each age group.) 
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S‐Figure 3: Graphical presentation of age‐dependent expression levels of miR‐34a target gene SIRT1 in plasma, 
PBMCs and brain samples of C57/B6 mice Panels (A, B, C) show line graphs representing average intensity of SIRT1 
expression, and trend lines depicting expression trends in various age groups, separated into different panels, with neonatal 2 
to 28 days (d) in panel (a), and early adult from 2 months (m) to old age of 25 months in panel (b) in PBMCs, plasma and brain 
samples. (All graphs represent Mean ± SD; n = 3; three different biological samples from each age group.) 
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S‐Figure 4: Age‐dependent expression levels of miR‐34a target gene Bcl‐2 in blood and tissue samples of 
C57/B6 mice Panels (A, B, C) show average intensities of Bcl‐2 expression, and trend lines depicting expression in 
various age groups, in plasma,  brain  and PBMCs samples. All  graphs represent Mean ±  SD;  n = 3;  three different 
biological samples from each age group. 
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S‐Figure 5: RNA integrity analysis, using Agilent 2100 Bioanalyzer Panels (A) Table shows RNA Integrity Number 
(RIN)  for  PBMCs  and  brain  samples  across  the  age  groups  considered;  (B)  shows  the  representative  graphical 
representation of 28s, 18s, and small RNA bands observed during RNA integrity analysis for PBMCs and brain samples; (C) 
shows the representative graphical representation of small RNA bands as a small peak, and absence of 28s and 18s RNA 
peaks, as expected, in plasma samples during RNA integrity analysis. 
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S‐Table‐1: Statistical analysis of miR‐34a and miR‐196a expression in blood and tissue samples of C57/B6 mice. 
Tabular presentation of mean standard deviation calculation for miRs‐34a and 196a in PBMCs, plasma and brain samples. (n = 3, 
three different biological samples from each age group) 
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